Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial.

Authors

Jean Bourhis

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Jean Bourhis , Anne Auperin , Marc Alfonsi , xu Shan Sun , Michel Rives , Yoann Pointreau , Cedrik Lafond , Pierre Boisselier , Pierre Graff , Juliette Thariat , Yungan Tao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Radiotherapy (RT) potentiation with weekly (q1w) or standard every 3 weeks (q3w) cisplatin chemotherapy (CT) for locally advanced head and neck squamous cell carcinoma (HNSCC).

First Author: Yann Molin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

First Author: Robert L. Ferris

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.

First Author: Christophe Le Tourneau

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Impact of COVID19 pandemic on treatment outcome of locally-advanced head and neck squamous cell carcinoma (LA-HNSCC): IMPACCT study.

First Author: Pau Guillen Sentis